VEGFA and neoplasm: However, the design of VEGF therapy is costly, and one of the most critical problems associated with this therapy is the uncontrollable dose of VEGF delivered [15], which results in negative side effects in non-targeted tissues (hyperpermeable vessels, hypotension, stimulation of tumor growth, and uncontrolled neovascularization) [16].